PMID- 18268494
OWN - NLM
STAT- MEDLINE
DCOM- 20080422
LR  - 20220408
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 98
IP  - 4
DP  - 2008 Feb 26
TI  - CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide 
      a model for patients with poor prognosis.
PG  - 756-65
LID - 10.1038/sj.bjc.6604242 [doi]
AB  - Recent evidence supports the hypothesis that cancer stem cells are responsible 
      for tumour initiation and formation. Using flow cytometry, we isolated a 
      population of CD44+CD24(-) prostate cells that display stem cell characteristics 
      as well as gene expression patterns that predict overall survival in prostate 
      cancer patients. CD44+CD24(-) cells form colonies in soft agar and form tumours 
      in NOD/SCID mice when as few as 100 cells are injected. Furthermore, CD44+CD24(-) 
      cells express genes known to be important in stem cell maintenance, such as BMI-1 
      and Oct-3/4. Moreover, we can maintain CD44+CD24(-) prostate stem-like cells as 
      nonadherent spheres in serum-replacement media without substantially shifting 
      gene expression. Addition of serum results in adherence to plastic and shifts 
      gene expression patterns to resemble the differentiated parental cells. Thus, we 
      propose that CD44+CD24(-) prostate cells are stem-like cells responsible for 
      tumour initiation and we provide a genomic definition of these cells and the 
      differentiated cells they give rise to. Furthermore, gene expression patterns of 
      CD44+CD24(-) cells have a genomic signature that is predictive of poor patient 
      prognosis. Therefore, CD44+CD24(-) LNCaP prostate cells offer an attractive model 
      system to both explore the biology important to the maintenance and 
      differentiation of prostate cancer stem cells as well as to develop the 
      therapeutics, as the gene expression pattern in these cells is consistent with 
      poor survival in prostate cancer patients.
FAU - Hurt, E M
AU  - Hurt EM
AD  - Cancer Stem Cell Section, Laboratory of Cancer Prevention, Center for Cancer 
      Research, National Cancer Institute at Frederick, National Institutes of Health, 
      Frederick, MD 21702, USA. hurte@ncifcrf.gov
FAU - Kawasaki, B T
AU  - Kawasaki BT
FAU - Klarmann, G J
AU  - Klarmann GJ
FAU - Thomas, S B
AU  - Thomas SB
FAU - Farrar, W L
AU  - Farrar WL
LA  - eng
GR  - N01CO12400/CA/NCI NIH HHS/United States
GR  - N01-CO-12400/CO/NCI NIH HHS/United States
GR  - ImNIH/Intramural NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
DEP - 20080212
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD24 Antigen)
RN  - 0 (Hyaluronan Receptors)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Animals
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - CD24 Antigen/*metabolism
MH  - Flow Cytometry
MH  - Gene Expression Profiling
MH  - Humans
MH  - Hyaluronan Receptors/*metabolism
MH  - Male
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - *Models, Biological
MH  - Neoplasm Invasiveness
MH  - Neoplastic Stem Cells/*metabolism
MH  - Oligonucleotide Array Sequence Analysis
MH  - Phenotype
MH  - Prognosis
MH  - Prostate/*metabolism/pathology
MH  - Prostatic Neoplasms/*metabolism/*pathology
MH  - RNA, Messenger/genetics/metabolism
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Transplantation, Heterologous
MH  - Tumor Stem Cell Assay
PMC - PMC2259168
EDAT- 2008/02/13 09:00
MHDA- 2008/04/23 09:00
PMCR- 2009/02/26
CRDT- 2008/02/13 09:00
PHST- 2008/02/13 09:00 [pubmed]
PHST- 2008/04/23 09:00 [medline]
PHST- 2008/02/13 09:00 [entrez]
PHST- 2009/02/26 00:00 [pmc-release]
AID - 6604242 [pii]
AID - 10.1038/sj.bjc.6604242 [doi]
PST - ppublish
SO  - Br J Cancer. 2008 Feb 26;98(4):756-65. doi: 10.1038/sj.bjc.6604242. Epub 2008 Feb 
      12.